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D
ilated cardiomyopathy (DCM) is a myocardial disease characterized by ventricular dilation and reduced pumping power. Numerous factors, including infections, congenital defects, genetic mutations, and exposure to chemotherapeutic agents or alcohol, can damage the myocardium and predispose the heart to DCM. Familial DCM accounts for 20% to 50% of all cases, with mutations affecting genes encoding cytoskeletal proteins (eg, titin, troponin, α-tropomyosin) or proteins required for contraction (eg, phospholamban). 1 DCM is 1 of the leading causes of chronic heart failure (CHF).
Conventional treatments for DCM and CHF have much in common. Mainstays include medications that block the renin-angiotensin and sympathetic nervous systems. Use of ACE inhibitors, angiotensin receptor blockers, and β-blockers in CHF is associated with reduction in both mortality and morbidity. Blocking the respective G protein-coupled receptors (GPCRs) protects the myocardium from further damage because exaggerated activation of these neurohormonal stimuli is maladaptive, leading to cardiomyocyte death, ventricular remodeling, and further deterioration of cardiac function.
On the contrary, the use of inotropic agents in the treatment of heart failure has experienced ups and downs over the past 200 years. For >100 years, cardiac glycosides (digitalis) were the only effective therapy for CHF. Inotropes, including sympathomimetics, phosphodiesterase inhibitors, and calcium sensitizers developed in the late 20th century, improve short-term cardiac performance but in some cases increase mortality in the long run. 2 Their use is restricted to acute decompensation in CHF.
Despite these challenges, the quest for safe therapeutic agents to improve contractile performance of the failing heart has not ceased. 3 In this issue of Circulation, Ryba and colleagues 4 report the effect of long-term administration of TRV067, a novel ligand of the angiotensin II type 1 receptor (AT 1 R), on the structure and function of failing hearts in a genetic mouse model of DCM. Their data demonstrate that TRV067 performs both as an antagonist of canonical G αq -mediated signaling by the AT 1 R, as well as an agonist of β-arrestin-mediated signaling by that same AT 1 R. In the case of the latter pathway, sensitization of myofilament Ca 2+ -responsiveness occurs, promoting contractility.
GPCR ligands can manifest bias toward 1 or a subset of downstream signaling pathways, a phenomenon termed biased agonism. The alternative signaling pathways in some cases are mediated by a different subtype of G protein and in other cases are G protein-independent and rather β-arrestin-dependent, as in the case of TRV067 or its sister peptides, TRV023 and TRV027. Canonically, β-arrestins are terminators of G protein coupling recruited to agonist-bound receptors for the initiation of receptor desensitization and internalization. The concept of biased agonism or functional selectivity in GPCR signal transduction has led to a new wave of drug development. Next-generation GPCR ligands will not only be specific to a particular receptor subtype but may also exploit specificities toward enhancement of therapeutically desirable signals and avoidance of undesirable signals. For example, carvedilol, a nonselective β 1 , β 2 -blocker efficacious for CHF treatment, is a β-arrestinbiased agonist of both β 1 -and β 2 -adrenoceptors, 5, 6 and carvedilol-induced β-arrestin-biased β 1 -adrenoceptor signaling is cardioprotective. 7 The main focus of the current study 4 is the AT 1 Rmediated β-arrestin-dependent signaling of the peptide TRV067. The authors hypothesized that TRV067 would increase myofilament Ca 2+ -responsiveness and improve cardiac function and structure in DCM by β-arrestinbiased agonism. Their rationale is based on earlier studies, [8] [9] [10] [11] with 2 other related biased ligands TRV023 and TRV027. As with unbiased ligands, TRV023 and TRV027 effectively block the maladaptive G protein-dependent signaling of the AT 1 R by acting as angiotensin receptor blockers. However, they increase contractility of isolated myocytes with no change in Ca 2+ transients by a G protein-independent β-arrestin-dependent signaling cascade, 8, 9 suggesting that these ligands are also Ca 2+ sensitizers. In addition, short-term TRV023 restores myocardial contractile strength in rats subjected to chronic angiotensin II infusion 10 and in a mouse model of familial DCM. 11 In the current study, 4 the authors used the same Tm-E54K mice 11 expressing a cardiomyocyte-directed mutated α-tropomyosin (Tm). This mutation causes a constitutive decrease in the myofilament Ca 2+ response and produces a DCM-like phenotype. The investigators treated the Tm-E54K mice, along with nontransgenic (NTG) mice, with TRV067 or the nonbiased ligand losartan for 3 months and assessed cardiac structure and function and signaling pathway activation in vivo.
Echocardiography revealed DCM phenotypic changes in Tm-E54K mice with dilated, thin-walled hearts and reduced cardiac contractile function. Remarkably, TRV067 treatment restored depressed cardiac function in Tm-E54K mice to normal, whereas losartan had no effect. Structural improvement with TRV067 treatment, however, was modest. Isolated papillary muscle fibers from treated mice were subjected to an in vitro myofilament Ca 2+ -responsiveness assay. Fiber bundles from Tm-E54K mice manifested significantly reduced myofilament Ca 2+ sensitivity, and TRV067 treatment markedly improved maximum tension generation and myofilament Ca 2+ sensitivity. Losartan had no effect. These findings provide compelling evidence that TRV067 is a calcium sensitizer capable of increasing myocardial contractility without increasing oxygen consumption, an attribute superior to conventional inotropes.
To elucidate underlying signaling mechanisms contributing to the long-term inotropic effect of TRV067, heart lysates from treated mice were analyzed for various sarcomeric proteins and signaling proteins. Using ProQ diamond phosphoprotein staining, the authors found that TRV067 significantly altered phosphorylation of ventricular myosin light chain 2 and troponin T in Tm-E54K mice. The effect of TRV067 on myosin light chain 2 phosphorylation was further confirmed by immunoblotting. In addition, phosphorylation of cardiac troponin I-S23/S24 and phospholamban-S16 revealed a significant increase in TRV067-or losartan-treated Tm-E54K hearts. Phosphorylation of Akt, GSK-3β, and β-catenin was increased in Tm-E54K hearts compared with NTG mice. TRV067 or losartan completely blocked the phosphorylation of these kinases in Tm-E54K hearts, revealing their common role as blockers of this pathway. These effects coincided with induced expression of β-myosin heavy chain, a downstream target of β-catenin and a marker of maladaptive cardiac hypertrophy, in Tm-E54K hearts and attenuation of the β-myosin heavy chain expression with drug treatment.
Increased ERK1/2 phosphorylation was observed in TRV067-treated Tm-E54K and NTG hearts but not in losartan-treated hearts. TRV067 increased ribosomal S6 kinase 3 (RSK3), serum response factor, and myosin phosphatase target 1/2 phosphorylation in both NTG and Tm-E54K hearts, whereas losartan had no such effects. Similarly, only TRV067 increased sarcoplasmic/ endoplasmic reticulum Ca 2+ -ATPase 2 protein expression in Tm-E54K and NTG mice. Because ERK1/2 phosphorylation is activated by β-arrestin-2-biased agonism of the AT 1 R and is used as a marker for β-arrestin activation, 12 the authors attributed the distinct effects of TRV067 as β-arrestin-2-dependent. They confirmed RSK3 to be a kinase directly downstream of ERK1/2, first by a coimmunoprecipitation assay suggesting physical proximity among β-arrestin, ERK1/2, and RSK3 in mouse hearts, and second by demonstrating the lack of phosphorylation of the downstream targets RSK3, serum response factor, and myosin phosphatase target 1/2 in TRV067-treated neonatal rat cardiomyocytes after ERK1/2 or RSK inhibition. The dependence of myosin light chain 2, cardiac myosin-binding protein-C, and cardiac troponin I phosphorylation on RSK3 was also confirmed by an in vitro RSK3 kinase assay. Overall, these results strongly support the induction of a β-arrestin-mediated ERK1/2-RSK3 signaling in TRV067-treated hearts. TRV067 might improve myofilament Ca 2+ sensitivity by altering the phosphorylation of cardiac troponin I and myosin light chain 2. In addition, activation of the serum response factor and subsequent upregulation of sarcoplasmic/ endoplasmic reticulum Ca by recruiting Ca 2+ /calmodulin-dependent kinase II, 13 whereas carvedilol-induced β-arrestin-biased agonism of β 1 -adrenoceptor targets β-arrestin-1 to the nucleus and promotes cardiomyocyte survival.
14 To this end, Ryba et al 4 report that short-term TRV067 treatment increases β-arrestin localization to the sarcomere in neonatal rat cardiomyocytes. Future studies using cardiomyocytes from normal and DCM animals with long-term TRV067 treatment will be helpful to further establish the importance of the localization of β-arrestin and its role in myofilament Ca 2+ sensitivity. Given that TRV067 is a β-arrestin-biased ligand for the AT 1 R, it is likely that the cardioprotective effects of TRV067 are mediated by β-arrestin-1, β-arrestin-2, or both expressed in cardiomyocytes. However, direct evidence demonstrating the physiological significance of β-arrestins is lacking. Because β-arrestin-1 and β-arrestin-2 double knockout mice are embryonic lethal, further studies using inducible β-arrestin knockout mice or their hybrids with Tm-E54K mice are warranted. It is important to note that systemic administration of TRV067 is capable of activating the cardiomyocyte AT 1 R-β-arrestin signaling cascade and this same pathway in other tissues, such as the vasculature and kidney, which may indirectly affect cardiac function. Tissue-specific β-arrestin knockout mice would be a well-suited model for studying the significance of the extracardiac AT 1 R-β-arrestin signaling.
Whether β-arrestin-biased AT 1 R signaling is translatable to clinical use remains to be tested. A technical barrier is that existing biased peptide ligands have short in vivo half-lives (2-13 minutes) precluding their long-term use in human. Tilley et al 15 reported that troglitazone, a thiazolidinedione antidiabetic agent now withdrawn from the market, stimulates β-arrestin-2-dependent cardiomyocyte contractility by AT 1 R. In HEK293 cells, troglitazone causes β-arrestin recruitment and AT 1 R internalization but does not induce the G αq -activated second messenger diacylglycerol. Nevertheless, the activity of troglitazone is much lower than that of angiotensin II in these assays (effective concentration=50 μM). Development of novel small-molecule β-arrestin-biased AT 1 R agonists could provide a means to improve contractile performance and concurrently harness the traditional benefits of angiotensin receptor blockers in reducing myocardial workload and reversing remodeling of failing hearts.
One important issue remaining to be addressed is whether cardioprotective β-arrestin signaling must be activated through AT 1 R. Because the expression levels of AT 1 R are relatively low in cardiomyocytes and many GPCRs other than AT 1 R are expressed in cardiomyocytes, stimulation of cardiac GPCRs with their respective β-arrestin-biased ligands may also exert protective effects by selectively activating β-arrestin signaling in the heart. If AT 1 R-β-arrestin signaling is not necessarily required but rather β-arrestin activation in cardiomyocytes by other GPCRs is sufficient, then combination therapy with angiotensin receptor blockers and small-molecule β-arrestin-biased ligands targeting other GPCRs might be an attractive alternative to the development of small-molecule β-arrestinbiased AT1R agonists. In the end, this excellent study underscores the validity of a biased signaling approach in the treatment of DCM and enhances the prospect that this strategy may emerge 1 day with clinical relevance.
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